RecruitingStrokeAphasia
pBFS-guided Multi-target cTBS for Aphasia After Stroke
Eligible age
35–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
In this study, a randomized, double-blind, parallel-controlled trial was employed to evaluate the effectiveness and safety of personalized brain functional sectors (pBFS) technology-guided continuous theta burst stimulation (cTBS) on the inferior frontal gyrus (IFG) combined with the superior temporal gyrus (STG) and the superior frontal gyrus (SFG) for language function recovery in post-stroke aphasic patients.
Sponsor: Changping Laboratory
You may qualify if…
- ✓ The patient's age ranges from 35 to 75 years old (including 35 and 75 years old);
- ✓ Meet the diagnostic criteria for ischemic stroke (according to the guidelines developed by the American Heart Association/American Stroke Association in 2019 and the guidelines developed by the Neurology Branch of the Chinese Medical Association in 2018) or meet the diagnostic criteria for hemorrhagic stroke (according to the guidelines developed by the American Heart Association/American Stroke Association in 2022 and the guidelines developed by the Neurology Branch of the Chinese Medical Association in 2019) ，with lesions located in the left hemisphere, and a duration of illness ranging from 15 days to 6 months.
- ✓ Diagnosed as aphasia patient according to the Chinese version of Western Aphasia Battery (WAB), with a WAB-aphasia quotient of less than 93.8 points;
- ✓ First onset of stroke;
- ✓ Normal language function before the onset of stroke, and the patient's native language is Chinese with at least 6 years of education;
- ✓ Understand the trial and signed the informed consent form.
You may not qualify if…
- ✕ Combined dysarthria (NIHSS item 10 score ≥2 points);
- ✕ Aphasia caused by bilateral hemisphere stroke, brain tumor, traumatic brain injury, Parkinson's disease, motor neuron disease, or other diseases；
- ✕ Patients with implanted electronic devices such as cardiac pacemakers, cochlear implants, or other metal foreign bodies, or those with MRI contraindications such as claustrophobia or TMS treatment contraindications;
- ✕ History of epilepsy;
- ✕ Patient with concomitant severe systemic diseases affecting the heart, lungs, liver, kidneys, etc., and uncontrolled by conventional medication, as detected and confirmed through laboratory testing and examination;
- ✕ Patients with consciousness disorders (NIHSS 1(a) score ≥1);
- ✕ Patients with malignant hypertension;
- ✕ Patients with severe organic diseases, such as malignant tumors, with an expected survival time of less than 1 year;
Source: ClinicalTrials.gov · NCT05957445 · last updated 2025-04-04